Hetrombopag Olamine
Phase 3Small molecule
Hetrombopag Olamine is a small molecule that works as a Thrombopoietin Receptor Agonist.[2] It is being investigated across 6 indications, with its most advanced program in Phase 3.[1]
Hetrombopag Olamine is one of 157 small molecule programs targeting Aplastic Anemia. It is currently in Phase 3.
6
Indications
18
Total Trials
5
Active Trials
156
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
804 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Rydapt
NovartisPhase 3
Fludara
SanofiPhase 3
Nexavar
BayerPhase 3
Busulfex
Akero TherapeuticsPhase 3
Empaveli
GileadPhase 3
Velcade
SShilpa Grover, MD, MPH
Phase 3
Zarnestra
KKura Oncology, Inc.
Phase 3
Zolinza
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Revuforj
SSyndax Pharmaceuticals
Phase 3
Bicnu
MMelissa K Accordino
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Thrombocytopenic Purpura3 trials
Severe Aplastic Anemia3 trials
Thrombocytopenia3 trials
Tics2 trials
6 more indications
Acute Myeloid Leukemia1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hetrombopag Olamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details